[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369340-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-369340-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","correlation-analysis-of-invasive-disease-free-survival-and-overall-survival-in-a-real-world-population-of-patients-with-hrthher2-early-breast-cancer","Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HRþ/HER2– early breast cancer","","Overall survival (OS) is the gold standard oncology end point but often demands extended follow-up to accumulate enough events. Invasive disease-free survival (iDFS) can be assessed sooner and is used as an objective, clinically meaningful alternative in early breast cancer. This retrospective, patient-level real-world study evaluated whether iDFS can serve as a surrogate for OS in adjuvant HRþ/HER2– early breast cancer using ConcertAI Patient360 data, January 1995 to April 2021.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/correlation-analysis-of-invasive-disease-free-survival-and-overall-survival-in-a-real-world-population-of-patients-with-hrthher2-early-breast-cancer/369340/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/correlation-analysis-of-invasive-disease-free-survival-and-overall-survival-in-a-real-world-population-of-patients-with-hrthher2-early-breast-cancer/369340.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why is overall survival (OS) challenging to use as the primary endpoint?","Question",{"text":62,"@type":63},"OS requires extended follow-up periods to detect a sufficient number of events for powered analysis, which can delay primary endpoint use in some oncology trials.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What dataset and study design were used to assess iDFS as a surrogate for OS?",{"text":67,"@type":63},"A retrospective analysis used patient-level data from the ConcertAI Patient360 database from January 1995 to April 2021 in HRþ/HER2– early breast cancer patients receiving adjuvant endocrine therapy.",{"name":69,"@type":60,"acceptedAnswer":70},"What were the study’s main findings on the iDFS–OS relationship?",{"text":71,"@type":63},"iDFS and OS showed a positive, very strong, clinically relevant correlation, with strong agreement across correlation measures (Spearman ρ and iterative multiple imputation ρ) and an R2 indicating that iDFS accounted for a large share of OS variation.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},369340,1790595590,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1002/cncr.35817  \nORIGINAL ARTICLE  \nCorrelation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HRþ/HER2– early breast cancer  \nStephanie L. Graff MD, FACP, FASCO1  | Sara M. Tolaney MD, MPH2  |  \nLowell L. Hart MD, FACP3,4 | Pedram Razavi MD, PhD5 | Wolfgang Janni MD, PhD6 | Lee S. Schwartzberg MD, FACP7 | Andriy Danyliv PhD8 | Murat Akdere PharmD8 | Ilia Ferrusi PhD9 | Rishi Rajat Adhikary PhD10 | Joyce A. O’Shaughnessy MD 11  \n1Brown University Health Cancer Institute, Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA 2Dana-Farber Cancer Institute, Boston, Massachusetts, USA  \n3Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, Florida, USA 4Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA 5Memorial Sloan Kettering Cancer Center, New York, New York, USA  \n6Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany 7Renown Health-William N. Pennington Cancer Institute, Reno, Nevada, USA 8Novartis Pharma AG, Basel, Switzerland 9Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA  \n10Novartis Healthcare Pvt., Ltd, Hyderabad, Telangana, India  \n11Texas Oncology/Baylor University Medical Center, Dallas, Texas, USA  \nCorrespondence  \nStephanie L. Graff, 593 Eddy St, George 304, Providence, RI 02903, USA.  \nEmail: [sgraff1@brownhealth.org](sgraff1@brownhealth.org)  \nFunding information  \nNovartis Pharmaceuticals Corporation  \nAbstract  \nBackground: Overall survival (OS) is the gold standard for assessing clinical benefit in oncology but requires extended follow-up to detect sufficient events. Invasive disease-free survival (iDFS) requires shorter follow-up times and is considered an objective and clinically meaningful end point in early breast cancer (EBC) trials. The authors assessed iDFS as a surrogate end point for OS in adjuvant HRþ/HER2– EBC using real-world patient-level data.  \nMethods: A retrospective analysis was conducted on patient data from the ConcertAI Patient360 database (January 1995–April 2021). Key inclusion criteria: age ≥18 years, stage II or III (AJCC 8th Edition) HRþ/HER2– EBC, prior surgery, adjuvant endocrine therapy (ET). Spearman ρ, iterative multiple imputation ρ (IMI; 0.8–1 considered “very strong”), and R2 (clinical relevance R2 ≥ 0. 70) were used to assess iDFS–OS relationship. Subgroup analyses included ET (nonsteroidal aromatase inhibitor or tamoxifen), stage, menopausal status, nodal status, prior (neo)adjuvant chemotherapy, and prior radiotherapy.  \nResults: A total of 3133 patients were included (1103 [35.2%] iDFS events; 554 [17.7%] OS events); mean age was 58.4 years, 98.8% were female, 29. 9% were premenopausal, and 80. 9% had stage II disease. Median follow-up time was 55.1 months. iDFS and OS exhibited a positive, very strong, clinically relevant correlation (Spearman ρ: 0.88 [0.87–0.89]; IMI ρ: 0.83 [0.79–0.86]; both p \u003C .0001). iDFSaccounted for 82% of variation in OS (R2 = 0.82). Results of all subgroup analyses were consistent with overall population.  \nConclusions: This patient-level real-world analysis demonstrated very strong, positive correlations between iDFS and OS, supporting the use of iDFS as a reliable primary end point in adjuvant HRþ/HER2– EBC.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2025 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2025;e35817.  \n[https://doi.org/10.1002/cncr.35817](https://doi.org/10.1002/cncr.35817)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 8  \nKEYWORDS  \ncorrelation analysis, HRþ/HER2– early breast cancer, invasive disease-free survival, overall survival, real ","cbCaisieVQk1MfkE","https://ap.wps.com/l/cbCaisieVQk1MfkE","pdf",955931,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## OS as the gold standard and follow-up challenges\n## Surrogate endpoints and role of iDFS\n## Validation approaches using RCT data","[{\"question\":\"Why is overall survival (OS) challenging to use as the primary endpoint?\",\"answer\":\"OS requires extended follow-up periods to detect a sufficient number of events for powered analysis, which can delay primary endpoint use in some oncology trials.\"},{\"question\":\"What dataset and study design were used to assess iDFS as a surrogate for OS?\",\"answer\":\"A retrospective analysis used patient-level data from the ConcertAI Patient360 database from January 1995 to April 2021 in HRþ/HER2– early breast cancer patients receiving adjuvant endocrine therapy.\"},{\"question\":\"What were the study’s main findings on the iDFS–OS relationship?\",\"answer\":\"iDFS and OS showed a positive, very strong, clinically relevant correlation, with strong agreement across correlation measures (Spearman ρ and iterative multiple imputation ρ) and an R2 indicating that iDFS accounted for a large share of OS variation.\"}]","Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HRþ/HER2– early breast cancer | PDF",1790182131,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a00afa572e063303638b63eda2a5b8d.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/093ee2196f12a3b755ccabe6db9ff9b1.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20cfd1e4ef8c8c9d5e15cb974a40f3f0.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43a42a2c4ffbc6d61fbdf549a6a1dd6c.webp",980,1287]